Floatz logo

Solu-Cortef

Muscle Weakness

Mahidol UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Muscle Weakness cohort.

Asset / SponsorPhaseRating
bio101
Biophytis
Phase 2B
ERGOCALCIFEROLUM
Brigham and Women's Hospital
D

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →